Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Histidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | CTSC | P53634 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histidine SCHEMBL1675273 | 1.00 | CYP3A4 (0.32) | CYP3A4SLC7A5CTSCCYP1A2 | |
| Histidine SCHEMBL790243 | 1.00 | CYP3A4 (0.32) | CYP3A4SLC7A5CTSCCYP1A2 | |
| Histidine SCHEMBL3490081 | 1.00 | CYP3A4 (0.32) | CYP3A4SLC7A5CTSCCYP1A2 | |
| Histidine SCHEMBL3088582 | 1.00 | CYP3A4 (0.32) | CYP3A4SLC7A5CTSCCYP1A2 | |
| Histidine SCHEMBL18280908 | 0.96 | CYP3A4 (0.30) | CYP3A4SLC7A5CTSC | |
| D-Histidine SCHEMBL11606906 | 0.96 | SLC7A5 (0.35) | CYP3A4SLC7A5CTSCCYP1A2 | |
| Histidine SCHEMBL27902238 | 0.96 | SLC7A5 (0.35) | CYP3A4SLC7A5CTSCCYP1A2 | |
| Histidine SCHEMBL2586203 | 0.96 | SLC7A5 (0.35) | CYP3A4SLC7A5CTSCCYP1A2 | |
| Histidine SCHEMBL2586200 | 0.96 | SLC7A5 (0.35) | CYP3A4SLC7A5CTSCCYP1A2 | |
| Dl-Phenylalanine SCHEMBL29201498 | 0.93 | ALPI (0.41) | SLC7A5CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8926609-B2 | Treatment device and treatment method | OLYMPUS MEDICAL SYSTEMS CORP. (JP) | 2015-01-06 | — | — | US | disclosed |
| EP-2616090-A1 | STABILIZATION OF IMMUNOGLOBULINS THROUGH AQUEOUS FORMULATION WITH HISTIDINE AT WEAK ACIDIC TO NEUTRAL PH | Baxter International Inc (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130172885-A1 | TREATMENT DEVICE AND TREATMENT METHOD | OLYMPUS MEDICAL SYSTEMS CORP. (JP) | 2013-07-04 | — | — | US | disclosed |
| WO-2012037534-A1 | STABILIZATION OF IMMUNOGLOBULINS THROUGH AQUEOUS FORMULATION WITH HISTIDINE AT WEAK ACIDIC TO NEUTRAL PH | BAXTER INTERNATIONAL INC. (US) | 2012-03-22 | — | — | WO | disclosed |